Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab

Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn’s disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the α4β7 integrin. Since α4β7-expressing lymphocytes mainly infiltrate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarozza, Patrizio, Marafini, Irene, Laudisi, Federica, Troncone, Edoardo, Schmitt, Heike, Lenti, Marco Vincenzo, Costa, Stefania, Rocchetti, Irene, De Cristofaro, Elena, Salvatori, Silvia, Frezzati, Ludovica, Di Sabatino, Antonio, Atreya, Raja, Neurath, Markus F., Calabrese, Emma, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073927/
https://www.ncbi.nlm.nih.gov/pubmed/32024071
http://dx.doi.org/10.3390/jcm9020385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073927/
https://www.ncbi.nlm.nih.gov/pubmed/32024071
http://dx.doi.org/10.3390/jcm9020385

Ejemplares similares